Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation and investment deals, including YHL Diagnostics (688575.SH), InventisBio (688382.SH), Keymed Bio (2162.HK), New Horizon Health (6606.HK), Burning Rock (BNR.N), Revolution Medicine (RVMD.N), Xihua Scientific Co, Singleron Biotechnologies, Pinnacles Dx, FutureGen, Regor Therapeutics, etc. Prior to LAV, Stella was new product planning lead for oncology at Roche overseeing development strategy for early stage pipeline products in China and Asia Pacific region. Previously, Stella worked with ZS Associates, a worldwide management consulting firm in healthcare industry, as a consultant. Stella holds a B.S degree in molecular biology from Fudan University.